REGENXBIO (NASDAQ:RGNX) Upgraded by StockNews.com to “Hold” Rating

StockNews.com upgraded shares of REGENXBIO (NASDAQ:RGNX) from a sell rating to a hold rating in a research report sent to investors on Friday morning.

RGNX has been the subject of a number of other research reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $30.00 target price on shares of REGENXBIO in a report on Tuesday, January 21st. Raymond James initiated coverage on REGENXBIO in a research note on Friday, February 7th. They set an “outperform” rating and a $27.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of REGENXBIO in a research note on Wednesday, January 15th. The Goldman Sachs Group lowered REGENXBIO from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $38.00 to $14.00 in a research note on Tuesday, February 11th. Finally, Morgan Stanley reissued an “overweight” rating and set a $22.00 price target on shares of REGENXBIO in a research note on Friday, November 15th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, REGENXBIO currently has an average rating of “Moderate Buy” and a consensus price target of $33.88.

REGENXBIO Stock Performance

Shares of REGENXBIO stock opened at $6.34 on Friday. The stock has a market cap of $314.12 million, a price-to-earnings ratio of -1.26 and a beta of 1.35. The stock has a 50 day moving average price of $7.44 and a 200-day moving average price of $9.19. REGENXBIO has a one year low of $5.62 and a one year high of $24.26.

Institutional Investors Weigh In On REGENXBIO

Institutional investors and hedge funds have recently bought and sold shares of the company. Barclays PLC raised its position in REGENXBIO by 141.3% during the 3rd quarter. Barclays PLC now owns 116,024 shares of the biotechnology company’s stock valued at $1,217,000 after purchasing an additional 67,948 shares in the last quarter. Assenagon Asset Management S.A. raised its position in REGENXBIO by 53.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock valued at $6,621,000 after purchasing an additional 296,700 shares in the last quarter. BNP Paribas Financial Markets raised its position in REGENXBIO by 602.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company’s stock valued at $214,000 after purchasing an additional 17,533 shares in the last quarter. FMR LLC raised its position in REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,656 shares in the last quarter. Finally, Stifel Financial Corp raised its position in REGENXBIO by 13.3% during the 3rd quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company’s stock valued at $1,566,000 after purchasing an additional 17,563 shares in the last quarter. 88.08% of the stock is owned by institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.